Bharat Biotech

Bharat Biotech today said that trials have indicated that a booster shot of Covaxin neutralises the Delta and Omicron variants of Covid.

Hyderabad-based vaccine manufacturer Bharat Biotech on Friday said that it has received reports of COVID-19 vaccines other than Covaxin are being administered in children of age group 15-18 years in the country.

The Gavi vaccine alliance is in talks with Bharat Biotech over potential procurement of the company's Covaxin COVID-19 shot for the COVAX global vaccine distribution programme, a Gavi spokesperson told news agency Reuters on Thursday.

Bharat Biotech on Wednesday said no painkillers or paracetamol are recommended after being vaccinated with its COVID-19 vaccine Covaxin.

Bharat Biotech today announced that Covaxin, its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III trials.

Bharat Biotech's COVID-19 vaccine Covaxin has been approved for emergency use on children between the ages of 12 and 18 by the Drugs Controller General of India (DCGI), sources said.

Chief Justice of India NV Ramana on Thursday presented the Dr Ramineni Foundation's awards to vaccine maker Bharat Biotech's MD Krishna Ella and several others for their meritorious services.

Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.

The Covid Subject Expert Committee's recommendations on granting emergency use authorisation to Bharat Biotech's Covaxin for the 2-18 age group are being examined and additional information has been sought, Rajya Sabha was informed Tuesday.

Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among the general population.

Covaxin, the coronavirus vaccine developed by the government's medical research agency and Bharat Biotech, was found to have a 77.8 per cent efficacy rate against symptomatic COVID-19 in a long-awaited analysis published in The Lancet.

Covaxin, a vaccine developed by government's medical research agency and Bharat Biotech International Ltd., was found to have a 77.8% efficacy rate against symptomatic Covid-19 in a long-awaited analysis published in The Lancet.

People will need booster doses of the COVID-19 vaccine would be required if the COVID-19 virus gets mutated, said Chairman and Managing Director of Bharat Biotech, Dr Krishna Ella.

Vietnam has approved India's Covaxin vaccine for emergency use, the ninth to be endorsed in the country, the country's health ministry said on Wednesday.

US company Ocugen announced Friday that it had asked authorities for emergency use authorization for Covid-19 vaccine Covaxin, which was developed in India, for ages 2 to 18.

Bharat Biotech today said that trials have indicated that a booster shot of Covaxin neutralises the Delta and Omicron variants of Covid.

Hyderabad-based vaccine manufacturer Bharat Biotech on Friday said that it has received reports of COVID-19 vaccines other than Covaxin are being administered in children of age group 15-18 years in the country.

The Gavi vaccine alliance is in talks with Bharat Biotech over potential procurement of the company's Covaxin COVID-19 shot for the COVAX global vaccine distribution programme, a Gavi spokesperson told news agency Reuters on Thursday.

Bharat Biotech on Wednesday said no painkillers or paracetamol are recommended after being vaccinated with its COVID-19 vaccine Covaxin.

Bharat Biotech today announced that Covaxin, its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III trials.

Bharat Biotech's COVID-19 vaccine Covaxin has been approved for emergency use on children between the ages of 12 and 18 by the Drugs Controller General of India (DCGI), sources said.

Chief Justice of India NV Ramana on Thursday presented the Dr Ramineni Foundation's awards to vaccine maker Bharat Biotech's MD Krishna Ella and several others for their meritorious services.

Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.

The Covid Subject Expert Committee's recommendations on granting emergency use authorisation to Bharat Biotech's Covaxin for the 2-18 age group are being examined and additional information has been sought, Rajya Sabha was informed Tuesday.

Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among the general population.

Covaxin, the coronavirus vaccine developed by the government's medical research agency and Bharat Biotech, was found to have a 77.8 per cent efficacy rate against symptomatic COVID-19 in a long-awaited analysis published in The Lancet.

Covaxin, a vaccine developed by government's medical research agency and Bharat Biotech International Ltd., was found to have a 77.8% efficacy rate against symptomatic Covid-19 in a long-awaited analysis published in The Lancet.

People will need booster doses of the COVID-19 vaccine would be required if the COVID-19 virus gets mutated, said Chairman and Managing Director of Bharat Biotech, Dr Krishna Ella.

Vietnam has approved India's Covaxin vaccine for emergency use, the ninth to be endorsed in the country, the country's health ministry said on Wednesday.

US company Ocugen announced Friday that it had asked authorities for emergency use authorization for Covid-19 vaccine Covaxin, which was developed in India, for ages 2 to 18.